Global Vascular Grafts Market

A VEGF inhibitor is an inhibitor that prevents planned cell death by acting as an anti-apoptotic factor for hematopoietic cells. VEGF increases vascular permeability, which may make it easier for tumours to spread via the bloodstream and receive more oxygen and nutrients. The main types of vascular endothelial growth factor (VEGF) inhibitors are Avastin, Tecentriq, Cometriq, Eylea, and others. Avastin is a medication that helps people with wet age-related macular degeneration (AMD). It can also be employed to treat diabetic eye problems and other retinal issues. It's administered into the eye to help delay the loss of eyesight caused by certain disorders. The different routes of administration include oral, and intravenous and are used in oncology, ophthalmology, and others. The vascular endothelial growth factor (VEGF) inhibitor market research report is one of a series of new reports from The Business Research Company that provides vascular endothelial growth factor (VEGF) inhibitor market statistics, including vascular endothelial growth factor (VEGF) inhibitor industry global market size, regional shares, competitors with a vascular endothelial growth factor (VEGF) inhibitor market share, detailed vascular endothelial growth factor (VEGF) inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the vascular endothelial growth factor (VEGF) inhibitor industry. This vascular endothelial growth factor (VEGF) inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global vascular endothelial growth factor (vegf) inhibitor market grew from $8.27 billion in 2022 to $8.96 billion in 2023 at a compound annual growth rate (CAGR) of 8.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The vascular endothelial growth factor (vegf) inhibitor market is expected to grow from $12.11 billion in 2027 at a CAGR of 7.8%. The growing prevalence of cancer and macular degeneration diseases is expected to drive the vascular endothelial growth factor (VEGF) inhibitor market. For instance, in August 2022, according to this systematic review and meta-analysis published by the National Library of Medicine, a US-based medical library, age-related macular degeneration will affect 8–7% of the global population, with the illness affecting 196 million individuals in 2020 and rising to 288 million by 2040. Anti-vascular endothelial growth factor (anti-VEGF) agents halt the progression of the disease and improve vision. A vascular endothelial growth factor (VEGF) inhibitor slows and restricts tumor growth during cancers. Hence, the rising prevalence of cancer along with macular degeneration disease aids in the growth of the vascular endothelial growth factor (VEGF) inhibitor market over the forecast period. Side effects caused by VEGF inhibitors are expected to hinder the vascular endothelial growth factor (VEGF) inhibitor market. Side effects of treatment with VEGF-targeting angiogenesis inhibitors include hemorrhage and clots in the arteries, which results in a stroke or heart attack, hypertension, reversible posterior leukoencephalopathy syndrome, and impaired wound healing, and protein in the urine. For instance, Bevacizumab, a biosimilar drug approved by FDA, has side effects such as impaired wound healing, hypertension, bleeding, and gastrointestinal perforations. Side effects caused by VEGF inhibitors hinder the growth of the vascular endothelial growth factor (VEGF) inhibitor market. Key players operating in the industry are undergoing various collaborations and partnerships to expand their product portfolio by developing new products. For instance, in May 2020, AbbVie, a US-based biopharmaceutical company acquired Allergan, Inc., a US-based pharmaceutical company focused on eye care. This acquisition establishes a biopharma firm with leadership roles in vital therapeutic areas such as hematologic oncology, immunology, Allergan Aesthetics, and neuroscience. Furthermore, in January 2020, Exonate, a biotechnology company, collaborated with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson for the development of a new eye drop for the treatment of retinal vascular diseases. Exonerate developed small molecules that inhibit the production of pro-angiogenic vascular endothelial growth factor (VEGF) through the selective inhibition of serine/threonine-protein kinase (SRPK1)-mediated VEGF splicing. In May 2020, AbbVie Inc., a US-based biopharmaceutical company, acquired Allergan plc for an amount of $63 billion. This acquisition is expected to give AbbVie Inc. an enhanced long-term growth potential along with a growing dividend and investment in innovation in each of Allergan plc’s therapeutic categories. Allergan plc is an Ireland-based pharmaceutical company engaged in the manufacturing of drugs and medical devices in the field of eye care, medical aesthetics, gastroenterology, and the central nervous system. Major players in the vascular endothelial growth factor (VEGF) inhibitor market are Pfizer, Amgen, Roche, Xbrane Biopharma AB, Genentech Inc., AstraZeneca PLC., Bayer AG, Eli Lilly and Company and Allergan PLC. North America was the largest region in the vascular endothelial growth factor (VEGF) inhibitor market in 2022. Middle East is expected to be the fastest-growing region in the global vascular endothelial growth factor (VEGF) inhibitor market during the forecast period. The regions covered in the global vascular endothelial growth factor (VEGF) inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the vascular endothelial growth factor (VEGF) inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The vascular endothelial growth factor (VEGF) inhibitor market consists of sales of nexavar, sunitinib, nilotinib, pazopanib, and dasatinib. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global vascular endothelial growth factor (VEGF) inhibitor market is segmented - 1) By Drugs Type: Avastin, Tecentriq, Cometriq, Eylea, Other Drug Types 2) By Route Of Administration: Oral, Intravenous 3) By Application: Oncology, Ophthalmology, Other Applications

Peripheral vascular devices and equipment are used to treat peripheral vascular diseases which are slow and progressive blood circulation disorders caused by blockages, narrowing, or spasms in blood vessels outside the heart and brain including arteries and veins. The main types of peripheral vascular devices and equipment are peripheral vascular stents, percutaneous transluminal angioplasty balloons, catheters, PTA guide wires, atherectomy devices, chronic total Occlusion devices, aortic stents, synthetic surgical grafts, embolic protection devices, and inferior vena cava filters. The catheter is a tubular medical device for insertion into canals, vessels, passageways, or body cavities to permit injection or withdrawal of fluids or to keep a passage open. The applications involved are the treatment of peripheral blood vessels damaged and the treatment of peripheral blood vessels blockage. The various end-users are hospital applications and clinic applications. The peripheral vascular devices and equipment market research report is one of a series of new reports from The Business Research Company that provides peripheral vascular devices and equipment market statistics, including peripheral vascular devices and equipment industry global market size, regional shares, competitors with a peripheral vascular devices and equipment market share, detailed peripheral vascular devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the peripheral vascular devices and equipment industry. This peripheral vascular devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global peripheral vascular devices and equipment market size will grow from $7.77 billion in 2022 to $8.27 billion in 2023 at a compound annual growth rate (CAGR) of 6.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The peripheral vascular devices and equipment market size is expected to grow to $10.04 billion in 2027 at a CAGR of 5.0%. The peripheral vascular devices and equipment market is driven by the rising number of people with peripheral artery diseases. Peripheral artery diseases are caused when arteries in the human body are blocked by plaque consisting of fats, cholesterol, and other substances restricting their blood flow to important organs. Lower extremity peripheral artery disease (PAD) affects >230 million adults worldwide and is associated with increased risk of various adverse clinical outcomes (other cardiovascular diseases such as coronary heart disease and stroke and leg outcomes such as amputation. The disease is different in younger populations; but, the incidence rises sharply, with over 20% of people over 80 years old having PAD. According to the Center for Disease Control and Prevention (CDC), approximately 8.5 million people in the USA are suffering from peripheral artery diseases, of which 12-20% are aged above 60 years. Stringent approval processes, product recalls and failures act as a restraint to the peripheral vascular devices and equipment market. Product recalls and failures potentially affect the brand image of the companies within this market. According to the US Food and Drug Administration (FDA), a product recall is made to perform corrective actions or prevent hazardous effects to patients. For instance, in January 2022, Medtronic was instructed to recall its artery-clearing HawkOne System due to reported injuries. \ To reduce incidences associated with the peripheral devices and ensure that the devices are safe and have the least adverse reactions, FDA is restricting devices for use, sending field safety notices, and making product recall to correct the devices. These stringent approval processes and regulatory policies may impact the peripheral devices and equipment market. Bio-absorbable stents are gaining popularity in the peripheral vascular devices and equipment market to eliminate thrombogenic risk factors and enhance clinical applicability. Bio-absorbable stents are made of natural soluble materials that disappear after insertion and eliminate the risk of late stent thrombosis. They help in protecting the body from inflammation or reduced blood flow due to late-stent thrombosis (a condition where the stent used for treatment stays inside the body for a prolonged period). Companies in this market are increasing their focus on developing and commercializing bio-absorbable stents. For instance, in 2020, Boston Scientific is demanded to start its Synergy Megatron bioabsorbable polymer coronary stent system. It is intended for large proximal vessels, including over main, bifurcations, and ostial lesions. It is made in 3.5 mm to 5.0 mm diameters. It owns enhanced strength and the capacity to create tapered vessels. In January 2022, the U.S Food and Drug Administration issued notice to Medtronic plc for Class I medical device recall for its HawkOne System for clearing out clogged arteries. The notice was issue after certain instances of injuries were reported. In September 2021, Boston Scientific, a US-based manufacturer of medical devices acquired Devoro Medical, Inc for an undisclosed amount. This acquisition of devoro medical inc will add the WOLF platform and advances efforts to ensure physicians have the right tools to improve procedural efficiencies. Devoro Medical, Inc., is a US-based manufacturer of medical technology. Major players in the peripheral vascular devices and equipment market are Medtronic, Boston Scientific Corporation, Abbott, Cook group, Angiomed GmbH & Co., Medizintechnik KG, Terumo Corporation, ENDOLOGIX Inc., Bolton medical Inc., and JOTEC. North America was the largest region in global peripheral vascular devices and equipment market in 2022. Western Europe was the second-largest region in global peripheral vascular devices and equipment market. The regions covered in the peripheral vascular devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the peripheral vascular devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, and Australia. The peripheral vascular devices and equipment market consist of sales of peripheral vascular stents, percutaneous transluminal angioplasty balloons, PTA drug-eluting balloons, embolic protection devices, inferior vena cava filters, Aortic stent-grafts, synthetic surgical drafts, and peripheral guide wires. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global peripheral vascular devices and equipment market is segmented - 1) By Type: Peripheral vascular stents, Percutaneous transluminal angioplasty balloons, Catheters, PTA guide wires, Atherectomy devices, Chronic total acclusion devices, Aortic stents, Synthetic surgical grafts, Embolic protection devices, Inferior vena cava filters 2) By End User: Hospital applications, Clinic applications, 3) By Application: Treatment of Peripheral Blood Vessels Damaged, Treatment of Peripheral Blood Vessels Blockage

Cardiovascular surgery devices and equipment are used in cardiac surgery and other cardiovascular procedures performed to repair structural defects of the cardiovascular system and damaged or blocked valves and vessels. The main product types in the cardiovascular surgery devices and equipment are beating heart surgery systems, cardiopulmonary bypass equipment, cardiac ablation devices, and perfusion disposables. Cardiopulmonary bypass equipment is used in open-heart surgeries and is operated by perfectionists. The various applications are congenital heart defects, cardiac arrhythmia, coronary heart disease, congestive heart failure, and other applications. These are used in home and ambulatory care, hospitals, diagnostic laboratories, and research laboratories. The cardiovascular surgery devices and equipment market research report is one of a series of new reports from The Business Research Company that provides cardiovascular surgery devices and equipment market statistics, including cardiovascular surgery devices and equipment industry global market size, regional shares, competitors with a cardiovascular surgery devices and equipment market share, detailed cardiovascular surgery devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the cardiovascular surgery devices and equipment industry. This cardiovascular surgery devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global cardiovascular surgery devices and equipment market size will grow from $1.68 billion in 2022 to $1.75 billion in 2023 at a compound annual growth rate (CAGR) of 3.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cardiovascular surgery devices and equipment market size is expected to grow to $1.91 billion in 2027 at a CAGR of 2.2%. The rising geriatric population along with the rising deaths related to cardiovascular disorders is driving the cardiovascular surgical devices market. According to American Heart Association (AHA), in the US, approximately 43.7 million aged above 60 suffered from cardiovascular disorders. It is also reported by AHA that death related to cardiac diseases amount to 17.3 million per year and is expected to rise to more than 23.6 million by 2030, worldwide. Due to these factors, a higher number of surgeries are being performed, thereby driving the market. The cardiovascular surgical devices market may be restrained due to stringent and longer approval processes by the regulatory authorities. According to a researcher from Harvard Business School, innovative first-mover products such as implantable defibrillators or transcatheter heart valves are delayed for approvals by FDA, thereby adding to the development cost to the manufacturer. For new cardiovascular devices (first-entrants), the innovator spends 7.2 months longer than the first follow-on innovator. For example, Edwards Lifesciences trans-catheter heart valve was approved in Europe 4 years before it was approved in the USA. The study also estimated the financial loss associated with the delay in getting the approval. The delay may cost firms an average of $6.7 million to the already existing $94 million average prices to introduce a new medical device to market, thereby hampering companies’ pursuit of innovations. Companies in the cardiovascular surgery devices and equipment market are investing in second-generation bioresorbable stents and as well rectifying the glitches which occurred in the earlier version of bioresorbable stents. This advancing segment is poised to garner $247 million by 2025. Due to the all-new device features such as thinner strut thicknesses, faster resorption times, and better radial force, these are expected to grow at a higher growth rate. A higher elective procedure volume due to the less-invasive nature of PCIs, when compared to coronary artery bypass grafting, is expected to drive bioresorbable stents adoption. For instance, Amaranth Medical has developed three medical devices with thinner strut thickness, the latest bearing a magnitude of 100 microns. The U.S. Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH) made public, its priority list for medical device guidance documents. This would allow the companies in promoting innovation and as well save them from the stringent consequences of non-approval of any product. Thus, a clearer and transparent approval method would drive the cardiovascular surgical devices market in the future. Major players in the cardiovascular surgery devices and equipment market are Abbott Laboratories, Boston Scientific Corporation, Cook Medical, C.R.Bard, Abiomed, St.Jude medical, Angiodynamics Inc., Transmedics, Terumo cardiovascular systems corporation, and Edwards Life Science Corporation. North America was the largest region in the global cardiovascular surgery devices and equipment market in 2022. Western Europe was the second-largest region in the global cardiovascular surgery devices and equipment market. The regions covered in the cardiovascular surgery devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cardiovascular surgery devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and USA. The cardiovascular surgery devices and equipment market consist of sales of perfusion disposables, beating heart surgery systems, cardiopulmonary bypass equipment, and cardiac ablation devices that are used for cardiovascular surgeries. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cardiovascular surgery devices and equipment market is segmented - 1) By Product Type: Beating heart surgery systems, Cardiopulmonary Bypass Equipment, Cardiac Ablation Devices, Perfusion Disposables 2) By End User: Home and Ambulatory care, Hospitals, Diagnostic laboratories, Research laboratories 3) By Application: Congenital Heart Defects, Cardiac Arrhythmia, Coronary Heart Disease, Congestive Heart Failure, Other Applications

Medical equipment are devices that can be instrument, apparatus or machine that can be used in the prevention, diagnosis or treatment of illness or disease, or for detecting, measuring, restoring, correcting or modifying the structure or function of the body for health purpose. The main types of medical equipment are in-vitro diagnostics, dental equipment and supplies, ophthalmic devices, diagnostic imaging equipment, cardiovascular devices, hospital supplies, surgical equipment, orthopedic devices, patient monitoring devices, diabetes care devices, nephrology and urology devices, ENT devices, anesthesia and respiratory devices, neurology devices, and wound care devices. In-vitro diagnostics are tests done on samples like blood or tissue that is taken from the human body. In-vitro diagnostics will detect diseases or other conditions and are used to monitor a person’s overall health to cure, treat, or prevent diseases. The type of expenditure involved is public and private. The various product are instruments/equipment and disposables. The various end users involved are hospitals and clinics, homecare, diagnostics centres, and others. The medical equipment market research report is one of a series of new reports from The Business Research Company that provides medical equipment market statistics, including medical equipment industry global market size, regional shares, competitors with a medical equipment market share, detailed medical equipment market segments, market trends and opportunities, and any further data you may need to thrive in the medical equipment industry. This medical equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global medical equipment market grew from $639.75 billion in 2022 to $695.05 billion in 2023 at a compound annual growth rate (CAGR) of 8.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The medical equipment market is expected to grow to $922.39 billion in 2027 at a CAGR of 7.3%. The rise in sedentary jobs, busy lifestyles, and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes, and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of chronic diseases such as diabetes. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% globally, by the year 2020. This is increasing the demand for medical devices used in the diagnosis, prognosis, and treatment of several diseases, thereby driving the demand for medical equipment. These factors are expected to increase the patient pool globally, thereby driving the market during the forecast period. Regulatory changes are likely to lead to increased costs relating to new product development and service offerings to clients. These changes are related to customer data protection such as the European Union's General Data Protection Regulation (GDPR), changes to equipment approval procedures, and other regulatory changes. For instance, according to cookieyed data 2021, in the US, PwC reported that 68% of 200 businesses surveyed intended to spend between $1 million and $10 million to comply with GDPR regulations. The GDPR regulation is an EU law on data protection and privacy of individuals residing in the European Union and the European Economic Area (EEA). It also regulates the export of personal data outside the EU and EEA areas. Additionally, the FDA is requesting more clinical data to support claims, therefore increasing the time to process 510(k)s by over 55% over the last decade. The potential loss of revenue due to delays in product release and additional costs incurred due to stringent approval processes puts a strain on investments relating to new product development, thereby affecting the growth of the medical equipment market. Device performance and patient data are available to healthcare service providers and are helping them to improve patient monitoring and overall care quality. Some companies are integrating medical device data with EMR (Electronic Medical Records) to improve transparency and collaboration. As consumer wearables are becoming more common, patient data volumes are increasing and companies are investing in deploying data management, warehousing, and security technologies. For example, Medtronic launched a tool to augment their cardiac devices to securely transfer device data to doctors and allow them to monitor the critical health indicators of their patients. Major companies in the medical equipment market include Medtronic Inc., Abbott Laboratories, Johnson & Johnson, Cardinal Health, Inc., Becton Dickinson, Siemens AG, STRYKER CORPORATION, Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., and Boston Scientific Corporation. North America was the largest region in the global medical equipment market in 2022. Asia-Pacific was the second largest region in the global medical equipment market. The regions covered in the medical equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the medical equipment market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The medical equipment market consists of sales of devices used in the diagnosis, treatment and monitoring of medical conditions. The market includes diagnostic devices, imaging devices, surgical devices and patient monitoring devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global medical equipment market is segmented - 1) By Type: In-Vitro Diagnostics, Dental Equipment And Supplies, Ophthalmic Devices, Diagnostic Imaging Equipment, Cardiovascular Devices, Hospital Supplies, Surgical Equipment, Orthopedic Devices, Patient Monitoring Devices, Diabetes Care Devices, Nephrology And Urology Devices, ENT Devices, Anesthesia And Respiratory Devices, Neurology Devices, Wound Care Devices 2) By Type of Expenditure: Public, Private 3) By Product: Instruments/Equipment, Disposables 4) By End User: Hospitals And Clinics, Homecare, Diagnostics Centers, Other End Users Subsegments Covered: Point-of-Care Diagnostics Devices And Equipment, Immunochemistry Diagnostic Devices And Equipment, Clinical Chemistry Diagnostics Devices And Equipment, Molecular Diagnostics Devices And Equipment, Microbiology Diagnostic Devices And Equipment, Hemostasis Diagnostic Devices And Equipment, Hematology Diagnostic Devices And Equipment, Immunohematology Diagnostic Devices And Equipment, Therapeutic Dental Equipment, General Dental Devices And Equipment, Dental Diagnostic Imaging Devices And Equipment, Dental Surgical Devices And Equipment, Vision Care Devices And Equipment, Cataract Surgery Devices And Equipment, Refractive Surgery Devices And Equipment, Diagnostic And Monitoring Ophthalmic Devices And Equipment, X-Ray Systems Devices And Equipment, Ultrasound Systems Devices And Equipment, Computed Tomography (CT) Scanners Devices And Equipment, Magnetic Resonance Imaging Systems Devices And Equipment, Cardiovascular Monitoring And Diagnostic Devices And Equipment, Nuclear Imaging Devices And Equipment, Cardiovascular Surgery Devices And Equipment, Cardiac Rhythm Management (CRM) Devices And Equipment, Interventional Cardiology Devices And Equipment, Defibrillator Devices And Equipment, Peripheral Vascular Devices And Equipment, Prosthetic Heart Valve Devices And Equipment, Electrophysiology Devices And Equipment, Cardiac Assist Devices And Equipment, Disposable Hospital Supplies, Sterilization Equipment And Disinfectants, Mobility Aids And Transportation Equipment, Operating Room Equipment, Surgical Sutures And Staples, Handheld Surgical Devices And Equipment, Electrosurgical Devices And Equipment, Joint Reconstruction Devices And Equipment, Spinal Surgery Devices And Equipment, Trauma Fixation Devices And Equipment, Orthobiologics Devices And Equipment, Arthroscopy Devices And Equipment, Orthopedic Braces And Support Devices And Equipment, Craniomaxillofacial (CMF) Devices And Equipment, Orthopedic Prosthetics, Orthopedic Accessories,, Fetal And Neonatal Monitoring Devices, Weight Monitoring And Body Temperature Monitoring Devices And Equipment, Vital Parameter Monitoring Devices And Equipment, Remote Patient Monitoring Devices And Equipment, Blood Glucose Test Strips, Insulin Pens, Syringes, Pumps And Injectors, Lancing Devices And Equipment, Continuous Glucose Monitoring Devices And Equipment, Blood Glucose Meters, Dialysis Devices And Equipment, Urinary Stone Treatment Devices And Equipment, Urinary Incontinence & Pelvic Organ Prolapse Devices And Equipment, Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment, Endoscopy Devices And Equipment, Hearing Aid Devices And Equipment, Hearing Diagnostic Devices And Equipment, ENT Surgical Devices And Equipment, Hearing Implants, Voice Prosthesis Devices And Equipment, Nasal Splints, Respiratory Devices And Equipment (Therapeutic And Diagnostic), Anesthesia Machines, Anesthesia Disposables, Respiratory Disposables, Cerebrospinal Fluid Management (CSF) Devices And Equipment, Interventional Neurology Devices And Equipment, Neurosurgery Devices And Equipment, Neurostimulation Devices, Traditional Adhesive Dressings, Negative-pressure Wound Therapy (NPWT), Traditional Gauze Dressings, Advanced Wound Care Devices

An intravascular catheter is a device typically comprised of a hollow fibre through which blood flows and an immunoisolating membrane separates the transplanted cells from the blood. The intravascular catheters are used for the administration of fluids, medication, blood products, and nutrition, which typically goes into a large vein in the arm or chest. The main intravascular catheter products include short PIVC and integrated/closed PIVC. Short peripheral intravenous catheters (PIVC) are less than or equal to 3 inches in length and are used for intravenous medication and are predominantly inserted in general wards. The different intravascular catheter applications include oncology, gastroenterology, renal disease, infectious diseases and other applications which are used by end-users including hospitals, clinics, ambulatory surgical center and homecare. The intravascular catheters market research report is one of a series of new reports from The Business Research Company that provides intravascular catheters market statistics, including intravascular catheters industry global market size, regional shares, competitors with an intravascular catheters market share, detailed intravascular catheters market segments, market trends and opportunities, and any further data you may need to thrive in the intravascular catheters industry. This intravascular catheters market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global intravascular catheters market size grew from $5.9 billion in 2022 to $6.66 billion in 2023 at a compound annual growth rate (CAGR) of 12.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The intravascular catheters market size is expected to grow to $10.32 billion in 2027 at a CAGR of 11.6%. The rising hospitalization rate owing to the high prevalence of chronic diseases is driving the growth of the intravascular catheters market. Globally, the prevalence of chronic illnesses and ailments is rising. Intravascular catheters are used for taking samples for tests and fluids, nutrients, and blood intake during the treatment of chronic diseases. According to an estimation by a German healthcare company, Fresenius Medical Care, the number of people suffering from chronic kidney failure is expected to increase from 3.7 million patients in 2020 to 4.9 million by 2025. Therefore, the rising hospitalization rate owing to the high prevalence of chronic diseases is expected to propel the growth of the intravascular catheters market over the coming years. The product innovations are a key trend gaining popularity in the intravascular catheters market. Major players in the intravascular catheters market are focusing on innovation of new products with advanced features to strengthen their position. For instance, in July 2022, B. Braun Medical Inc., a German-based medical and pharmaceutical device manufacturing company, introduced Introcan Safety 2 IV Catheter with one-time blood control making IV access safer for the clinician by lowering the danger of blood exposure and needle stick accidents. Furthermore, in March 2022, Shockwave Medical Inc., a firm that creates and sells medical devices, introduced the Shockwave M5+ catheter is particularly made to treat calcified lesions in the iliac, femoral, iliofemoral, popliteal, infra-popliteal, and renal arteries in the lower limbs that are otherwise difficult to treat. In January 2021, Prunus Technology Co., Ltd., a Shenzhen-based developer and manufacturer of various medical equipment, acquired Biosensors International Group, Ltd for an undisclosed amount. Through this acquisition, Prunus Technology expanded into central venous catheters, pressure transducers, pulmonary artery catheters, pacing catheters, thrombolysis catheters, urinary catheters and other medical consumables. Biosensors International Group, Ltd. is a Singapore-based company specializing in the critical care consumables business. Major players in the intravascular catheters market are Cook Medical, Smiths Medical, Edwards Life Sciences Corporation, Medtronic Inc., Johnson & Johnson, McKesson Medical Surgical Inc., Terumo Corporation, Abbott Laboratories Inc., Boston Scientific Corp., Getinge AB, Coloplast Corp., Cardinal Health, Conavi Medical, Infraredx Inc., BD, MAQUET Holding BV & Co KG, Vitality Medical, BBraun, Koninklijke Philips NV, Lumend Corporation, COVIDien Ag, Acist Medical Systems, Biotronic SE, & COKG, Biosense Webster Inc., Cordis, QX Medical and Teleflex Corporated. North America was the largest region in the intravascular catheters market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravascular catheters market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the intravascular catheters market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The intravascular catheters market consists of sales of pulmonary artery catheters and pacing wires. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global intravascular catheters market is segmented - 1) By Product: Short PIVC, Integrated/Closed PIVC 2) By Application: Oncology, Gastroenterology, Renal Disease, Infectious Diseases, Other Applications 3) By End-Use: Hospitals, Clinics, Ambulatory Surgical Center, Homecare

Bone grafts and substitutes refer to a procedure in which bone defects are filled with bone grafts or with bone graft substitutes. Bone abnormalities that necessitate bone grafting are common in trauma and orthopedic operations. Bone grafting can be described as the envelopment and interdigitation of the donor bone tissue with the new bone deposited by the recipient. It is versatile, which replaces the lost bone tissue and enhances bone growth using natural mechanisms. The bone grafts and substitutes are used to replace and regenerate the lost bone, and can also restore proper facial contour. The main types of bone grafts and substitutes are allografts, synthetics, composites, polymers, bone morphogenic proteins (BMP), and others. Allograft bone grafts and substitutes refer to a tissue graft from a donor of the same species as the recipient. Allografts are commonly used in spinal fusion surgery. The various applications include spinal fusion, trauma, craniomaxillofacial, joint reconstruction, dental bone grafting, and others, which are used by several end users such as hospitals, surgical centres, clinics, and others. The bone grafts and substitutes market research report is one of a series of new reports from The Business Research Company that provides bone grafts and substitutes market statistics, including bone grafts and substitutes industry global market size, regional shares, competitors with a bone grafts and substitutes market share, detailed bone grafts and substitutes market segments, market trends and opportunities, and any further data you may need to thrive in the bone grafts and substitutes industry. This bone grafts and substitutes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry. The global bone grafts and substitutes market size grew from $2.95 billion in 2022 to $3.16 billion in 2023 at a compound annual growth rate (CAGR) of 7.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The bone grafts and substitutes market size is expected to grow to $3.92 billion in 2027 at a CAGR of 5.5%. The rise in the incidence of musculoskeletal disorders such as osteoporosis and tendonitis is expected to propel the growth of the bone grafts and substitutes market going forward. Musculoskeletal disorders are some types of injuries and disorders that affect the human body's movement and musculoskeletal system. These cause disorders in muscles, nerves, tendons, joints, cartilage, and spinal discs. As a result, due to an increase in musculoskeletal disorders, to an increase in demand for bone grafts and substitutes market. For instance, in March 2022, according to a Pediatric Orthopedic Consultant at Indian Spinal Injuries Centre, Delhi, there was a 50% rise in Pediatric Orthopaedic Cases due to poor posture of students during online classes. Also, in 2020, according to the report by Cleveland Clinic, a US-based medical service provider, about 200 million people had osteoporosis throughout the world and 54 million people were suffering from it in the US. Therefore, the increasing the growth of incidence of musculoskeletal disorders helps to increase the demand for bone grafts and substitutes market. New product innovations have emerged as the key trend gaining popularity in the bone grafts and substitutes market. Major companies operating in the bone grafts and substitutes market are focused on product innovations to meet consumer demand. For instance, in July 2021, Orthofix, a US-based company that manufactures bone graft devices, launched a new fiber bone-graft strip called the Orthofix fiberFUSE Strip, a sophisticated demineralized bone graft solution including cancellous bone. The utilization of Novel Fibers Strip is a great bone-graft strip for posterior cervical, posterior lumbar, and degenerative spinal surgery prevention. The fiberFuse Strip comprises mineralized cancellous and demineralized cortical bone fibers, which are used in the healing of bones. In March 2020, Orthofix International N.V, a US-based medical device company acquired the FITBONE lengthening system from Wittenstein SE for an undisclosed amount. Through this acquisition, Orthofix becomes the only orthopedic company that offers a comprehensive portfolio of internal and external fixation solutions for limb reconstruction. Wittenstein SE is a Germany-based company that manufactures products for bone grafts and substitutes. Major players in the bone grafts and substitutes market are Zimmer Biomet Dental, DePuy Synthes, Wright Medical Technology, Medtronic PLC., Stryker Corporation, NuVasive Inc., Arthrex Inc., Integra LifeSciences, Baxter International Inc., Musculoskeletal Transplant Foundation, Bacterin International Holdings, SeaSpine, LifeNet Health, AlloSource, DePuySynthes Inc., Biobank, GeistlichPharma AG, Smith & Nephew, OST Devloppement, Orthofix Holdings Inc., and TBF Tissue Engineering. North America was the largest region in the bone grafts and substitutes market in 2022. The regions covered in the bone grafts and substitutes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the bone grafts and substitutes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The bone grafts and substitutes market consist of sales of xenograft tissue, alloplast bone graft, autograft tissue and allograft tissue. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global bone grafts and substitutes market is segmented - 1) By Material: Allograft, Synthetic, Composites, Polymers, Bone Morphogenic Proteins (BMP), Other Materials 2) By Application: Spinal fusion, Trauma, Craniomaxillofacial, Joint reconstruction, Dental bone grafting, Other Applications 3) By End User: Hospitals, Surgical Centres, Clinics, Others End Users

Bifurcation lesions refer to a coronary artery constriction that occurs next to or involves the origin of a vital side branch one does not want to lose. It occurs when plaque deposits accumulate, and the artery becomes too small for adequate blood flow to your heart. The main types of bifurcation lesions are one-stent and two-stent. One-stent bifurcation lesions refer to a procedure where the side branch is provisionally stented if the intervention is required owing to clinical complaints, angiographic results, or other adjunctive variables. The main branch is stented first in this approach. The bifurcation angle is determined by the internal angle between the main and side branches. These types of bifurcation lesions are applied in coronary and peripheral vascular. The bifurcation lesions market research report is one of a series of new reports from The Business Research Company that provides bifurcation lesions market statistics, including bifurcation lesions industry global market size, regional shares, competitors with a bifurcation lesions market share, detailed bifurcation lesions market segments, market trends and opportunities, and any further data you may need to thrive in the bifurcation lesions industry. This bifurcation lesions market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global bifurcation lesions market size grew from $2.25 billion in 2022 to $2.4 billion in 2023 at a compound annual growth rate (CAGR) of 6.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The bifurcation lesions market size is expected to grow to $3.18 billion in 2027 at a CAGR of 7.2%. The increase in geriatric population is expected to drive the growth of the bifurcation lesions market. People whose age is more than 60 years are more likely to suffer a heart attack, a stroke, or develop coronary heart disease and heart failure than younger people. In such cases, bifurcation lesions help treat the blood clots to allow adequate blood flow to your heart. For instance, according to the United Nations Department of Economic and Social Affairs' September 2020 report, the population aged 65 and above is projected to rise from 9.3% in 2020 to around 16.0% in 2050. Furthermore, according to October 2021 published factsheet by World Health Organization, there will be 1.4 billion individuals over the age of 60 in the world by 2030, up from 1 billion in 2020. Therefore, the increasing geriatric population will drive the bifurcation lesions market. The advancement in devices used in imaging and procedures is a key trend that is gaining popularity in the bifurcation lesions market. Major companies operating in the market are concentrating their efforts on advancements in existing devices used in imaging and procedures. For instance, Advanced Bifurcation Systems (ABS), a clinical-stage medical device firm with a unique bifurcation stenting solution to standardize the treatment of all bifurcation lesions in coronary angioplasties, has a platform featuring the only modular self-aligning stent technology to evenly structure bifurcations. The ABS platform is a unique single system that reduces the need for repeat procedures and enables effective bifurcation stenting treatment. In September 2021, Boston Scientific Corporation, a US-based biomedical/biotechnology engineering firm and manufacturer of medical devices used in interventional medical specialties, acquired Devoro Medical, Inc. for an undisclosed amount. Through this acquisition, Boston Scientific will focus on clot management and commercialization using the WOLF Thrombectomy Platform developed by Devoro Medical. Innovative non-console and lytic-free WOLF technology use finger-like prongs to extract and remove thrombi in the arterial and venous systems to target and quickly trap blood clots. This technology will enhance and broaden its selection of interventional strategies for thromboemboli, including the AngioJet Thrombectomy System and the EkoSonic Endovascular System (EKOS). Devoro Medical, Inc is a US-based developer of a medical device intended to restore blood flow. Major players in the bifurcation lesions market are Boston Scientific Corporation, Terumo Medical Corporation, Spectranetics, Medtronic, Cardinal Health, Abbott, Tryton Medical Inc., Advanced Bifurcation Systems, and Cook Medical. North America was the largest region in the bifurcation lesions market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in bifurcation lesions market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the bifurcation lesions market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The bifurcation lesions market includes revenues earned by proximal main branch (MB), distal MB and side branch (SB). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.  The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global bifurcation lesions market is segmented - 1) By Types: One-Stent, Two-Stent 2) By Application: Coronary Vascular, Peripheral Vascular

Coronary atherectomy devices are used to remove atherosclerosis from coronary blood vessels. Atherectomy devices were developed to permit drilling, grinding, or sanding of atheroma, calcium, and excess cellular material from the site of coronary occlusion or stenosis. The main products of coronary atherectomy devices are directional atherectomy devices, orbital atherectomy devices, photo-ablative atherectomy devices, rotational atherectomy devices, and others. The rotational atherectomy device is a long catheter with an oval-shaped burr that is encrusted with microscopic diamond embedded surface tip. The various application involved are peripheral vascular, cardiovascular, and neurovascular that are used by end-users such as hospitals and surgical centers, ambulatory care centers, research laboratories, and academic institutes. The coronary atherectomy devices market research report is one of a series of new reports from The Business Research Company that provides coronary atherectomy devices market statistics, including coronary atherectomy devices industry global market size, regional shares, competitors with a coronary atherectomy devices market share, detailed coronary atherectomy devices market segments, market trends and opportunities, and any further data you may need to thrive in the coronary atherectomy devices industry. This coronary atherectomy devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global coronary atherectomy devices market grew from $0.18 billion in 2022 to $0.2 billion in 2023 at a compound annual growth rate (CAGR) of 10.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The coronary atherectomy devices market is expected to grow from $0.28 billion in 2027 at a CAGR of 8.5%. The increasing prevalence of cardiovascular diseases (CVDs) has resulted in an increased demand for atherectomy devices for the treatment of CVDs. The increased prevalence of cardiovascular diseases can be attributed to the use of smoking, physical inactivity, and an unhealthy diet. For instance, according to the Centers for Disease Control and Prevention, in 2020, heart diseases causes 697,000 deaths. It is a group of disorders of the heart and blood vessels and includes cerebrovascular disease, rheumatic heart disease, coronary heart disease, and other conditions. According to the British Heart Foundation, 2020, Coronary Heart Disease is responsible for around 64,000 deaths in the UK each year, an average of 180 people each day, or one death around every eight minutes. One in seven men and one in twelve women in the United Kingdom die from coronary heart disease. Therefore, increasing the prevalence of cardiovascular diseases is expected to drive the growth of the global coronary atherectomy devices market. During the forecast period, the long approval processes for medical devices are expected to restrain the growth of the coronary atherectomy devices market. Regulatory bodies have imposed strict labeling requirements, pre-market approval, medical device reporting, and the launching of products. These devices fall under the Class II category and are considered to be highly risky. Therefore, stringent government regulations may hamper the growth of the coronary atherectomy devices market. Large coronary atherectomy equipment market manufacturers are strategically partnering and collaborating with start-ups and mid-sized companies to broaden products and services. For instance, in 2021, Cardiovascular Systems, Inc. has announced the acquisition of peripheral support catheters from Wavepoint Medical LLC with an undisclosed amount. This acquisition helps Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company operate on developing and commercializing creative solutions for treating vascular and coronary disease. In July 2020, BD (Becton, Dickinson and Company), a US-based medical devices company, acquired Straub Medical AG for an undisclosed amount. The acquisition would allow BD to extend its offerings in the fields of thrombectomy and atherectomy and strenhthen its portfolio in stents, stent grafts, angioplasty and scoring balloons. Straub Medical AG is a Switzerland-based developer of medical atherectomy and thrombectomy devices. Major players in the coronary atherectomy devices market are Boston Scientific, Philips, Cardiovascular Systems, Spectranetics, Medtronic, Avinger, BIOTRONIK, Arterial Remodeling Technologies, Atrium Medical, and B. Braun Melsungen. North America was the largest region in the coronary atherectomy devices market in 2022. Western Europe was the second largest region in the global coronary atherectomy devices market report. Africa. was the smallest region in the global coronary atherectomy devices market. The regions covered in the global coronary atherectomy devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the coronary atherectomy devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The coronary atherectomy devices market consists of sales of directional atherectomy devices, orbital atherectomy devices, photo-ablative atherectomy devices, rotational atherectomy devices, and others that are used to treat coronary atherectomy. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global coronary atherectomy devices market is segmented - 1) By Product: Directional Atherectomy Devices, Orbital Atherectomy Devices, Photo-Ablative Atherectomy Devices, Rotational Atherectomy Devices, Other Products 2) By Application: Peripheral Vascular, Cardiovascular, Neurovascular 3) By End User: Hospitals & Surgical Centers, Ambulatory Care Centers, Research Laboratories & Academic Institutes